Cor Vasa 2006, 48(3):98-107 | DOI: 10.33678/cor.2006.035

The program of heart transplantation at IKEM from 31 January 1984 through 31 May 2005

Zora Dorazilová1,*, Ivan Málek2, Jan Pirk1, Mariana Podzimková2, Lenka Hošková2
1 Klinika kardiovaskulární chirurgie
2 Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika

Introduction:
Orthotopic heart transplantation (OHT) is currently considered standard treatment of patients with end-stage heart failure. The program of OHT in the Czech Republic was launched at the Institute for Clinical and Experimental Medicine (IKEM) on 31 January 1984 and, in October 2005, the first transplant recipient marked 21 years since his successful surgery. This presentation is an analysis of the benefits and limitations of the program of OHT at IKEM.

Methods:
Our group of patients includes 572 (480 males and 92 females) patients undergoing OHT; four males had repeat transplantation. The mean age of our patients was 47.5 years (± 11.3). The PATS clinical expert system was used for data storing and analysis (Dentrite Inc., Portland, OR). Data are processed using descriptive statistics, with cumulative survival calculated by Kaplan-Meier method.

Results:
When evaluating one-year survival rates of patients at IKEM since 1990, i. e., after five years of experience with OHT, the one-, 10- and 15-year survival rates among the 527 transplant recipients were 80.5%, 50.9%, and 29%, respectively. The underlying disease leading to end-stage heart failure was dilated cardiomyopathy in 49.3% and coronary heart failure in 39.6%, with other diagnoses making up 10%. The fate of patients after OHT is affected by a variety of risk factors. In our series, longer survival times were documented in patients with the diagnosis of dilated cardiomyopathy; females, and, among males, those receiving grafts from donors of the same gender. Better survival times were also seen in patients with cardiac grafts from donors below 45 years of age. The main problem we are faced with is the paucity of donor grafts, a major limitation to the number of OHT. The most frequent cause of death of transplant recipients was cardiac graft failure, occurring in 76 patients (33% of all deaths).

Conclusion:
Our results are consistent with data published in the latest (i. e., XXIst) Annual Report of the International Society for Heart and Lung Transplantation (ISHLT). Although no randomized studies have been conducted, it is generally accepted that heart transplantation undertaken after all other therapeutic options have been exhausted prolongs life and improves its quality.

Keywords: Heart transplantation; Waiting list; International registry; Graft failure; Mechanical cardiac support

Published: March 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dorazilová Z, Málek I, Pirk J, Podzimková M, Hošková L. The program of heart transplantation at IKEM from 31 January 1984 through 31 May 2005. Cor Vasa. 2006;48(3):98-107. doi: 10.33678/cor.2006.035.
Download citation

References

  1. Kočandrle V, Fabián J, Firt P. Transplantace srdce. Čas Lék Čes 1984;123:1297-302.
  2. Málek I. Transplantace srdce. Pohled kardiologa. 1. vyd. Praha: Triton, 2004:42:85.
  3. Kao W, McGee D, Liao J, et al. Does heart transplantation confer additional benefit over medical therapy to patients who have waited > 6 months for heart transplantation. J Am Coll Cardiol 1994;24:1547-551. Go to original source... Go to PubMed...
  4. Barnard CN. A human cardiac transplant: an interim report of successful operation performed at Groote Schuur Hospital, Capetown. S Afr Med J 1967;41:1271-4.
  5. Dreyfus G, Jebara V, Mihaileanu S, et al. Total orthotopic heart transplantation: an alternative to the standard technique. Ann Thorac Surg 1991;52:1181-4. Go to original source... Go to PubMed...
  6. Taylor DO, Edwards LB, Boucek MM, et al. The Registry of the International society for heart and lung transplantation: Twenty-first official adult heart transplant report - 2004. J Heart Lung Transplant 2004; 23:796-803. Go to original source... Go to PubMed...
  7. Meiser BM, Groetzner J, Kaczmarek I, et al. Tacrolimus or Cyclosporine: Which is the better partner for Mycofenalate Mofetil in heart transplant recipients? Transplantation 2004;78:591-8. Go to original source... Go to PubMed...
  8. Griepp RB, Stinson EB, Dong E, et al. Determinants of operative risk in human heart transplantation. Am J Surg 1971;122:192-7. Go to original source... Go to PubMed...
  9. Kakáč J, Málek I, Hrnčárek M, et al. Testování plicní hypertenze u kandidátů ortotopické transplantace srdce pomocí prostaglandinu E1. Cor Vasa 1996;38: 251-7.
  10. Libby P, Salomon RN, Payne PB, et al. Function of vascular wall cells related to development of transplantation associated coronary atheromatous disease. Transplant Proc 1989;21:3667-84.
  11. Grattan HT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-6. Go to original source...
  12. Straka F, Málek I, Staněk V, a spol. Koronární nemoc u pacientů po transplantaci srdce. Cor Vasa 1993;35: 267-75.
  13. Park JW, Merz M, Braun P, et al. Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation. J Heart Lung Transplant 1996;15:572-9.
  14. Kocík M, Janek B, Želízko M, et al. Influence of donor transmitted native atherosclerosis on prognosis after ortotopic heart transplantation. Cor Vasa 2005;45 Suppl:44.
  15. StGoar FG, Pinto FJ, Alderman EL, et al. Intracoronary ultrasound in cardiac transplant recipients: in vivo evidence of angiographically silent intimal thickening. Circulation 1992;85:979-87. Go to original source... Go to PubMed...
  16. Gregory C, Huang X, Pratt R, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995;59: 655-61. Go to original source... Go to PubMed...
  17. Kobashigawa JA, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998;66:507-15. Go to original source... Go to PubMed...
  18. Hegarová M, Podzimková M, Hošková L, et al. Mycophenolate-Mofetil vs. Azathioprine after OHTX. Results from the prospective randomized study. ESOT 2003; Abstract 264.
  19. Špinarová L, Toman J. Fluvastatin u pacientů po transplantaci srdce. Vnitř Lék 1998;44:13-6. Go to PubMed...
  20. Kobashigawa JA, Katznelson S, Laks M, et al. Effect of pravastatin on outcomes after cardiac transplation. N Engl J Med 1995;333:62-7. Go to original source... Go to PubMed...
  21. Keogh A, MacDonald P, Kaan A, et al. Efficiency and safety of pravastatin vs. simvastatin after cardiac transplantation. J Heart Lung Transplant 2000;19:529-37. Go to original source... Go to PubMed...
  22. Ventura HO, Malik FS, Mehre MR, et al. Mechanism of hypertension in cardiac transplantation and the role of cyclosporine. Current Opinion in Cardiol 1997;12:375-81. Go to original source... Go to PubMed...
  23. Hošková L, Málek I, Šedivý J, a spol. Lékové interakce cyklosporinu A. Cor Vasa 2002;44:481-6.
  24. Gao S, Schroeder J, Hunt S, et al. Acute myocardial infarction in cardiac transplant recipient. Am J Cardiol 1989;64:1093-7. Go to original source... Go to PubMed...
  25. Farge D, Julien J, Amrein C, et al. Effect of systemic hypertension on renal function and left vntricular hypertrophy in heart transplant recipients. J Am Coll Cardiol 1990;15:1095-101. Go to original source... Go to PubMed...
  26. Podzimková M, Gebauerová M, Málek I, a spol. Infekční komplikace nemocných po transplantaci srdce. Cor Vasa 1993;35:263-6.
  27. Kirklin JK, Naftel DC, Levine TB, et al. Cardiac transplant research database group: Cytomegalovirus after heart transplantation risk factors for infection and death: a multiinstitutional study. J Heart Lung Transplant 1994;13:394-404.
  28. Hošková L, Málek I, Podzimková M, a spol. Nádorová onemocnění u pacientů po Tx srdce. Cor Vasa 2002;44:77-80.
  29. Viklický O, Podzimková M, Matl I, et al. Renal function in cyclosporine-treated heart transplant recipients long-term follow-up. Cor Vasa 1999;41:131-4.
  30. Greenberg A, Thompson ME, Griffith BP, et al. Cyclosporine nephrotoxicity in cardiac allograft patients - a seven year follow-up. Transplantation 1990;50:589-93. Go to original source... Go to PubMed...
  31. Herrmann G, Simon R, Haverich A, et al. Left ventricular function, tricuspid incompentence and incidence of coronary artery disease late after orthotopic heart transplantation. Eur J Card Cor Surg 1989;3:2,111-7. Go to original source... Go to PubMed...
  32. Auricchio A, Klein H, Spinelli J. Pacing for heart failure: Selection of patients, techniques and benefits. Eur J Heart Failure 1999;1:275-9. Go to original source... Go to PubMed...
  33. Kettner J. Mechanické podpory krevního oběhu. Cor Vasa 2003;45:437-43.




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.